Original Article
Kidney International (1998) 53, 1519–1549; doi:10.1046/j.1523-1755.1998.00936.x
Vascular development and disorders: Molecular analysis and pathogenic insights
Peter Carmeliet and Désiré Collen
1Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, University of Leuven, Leuven, Belgium
Correspondence: Peter Carmeliet, Center for Transgene Technology and Gene Therapy, Campus Gasthuisberg, Herestraat 49, University of Leuven, Leuven B-3000, Belgium. E-mail: peter.carmeliet@med.kuleuven.ac.be
Keywords:
blood vessel, angiogenesis, pericyte, atherosclerosis, coagulation, gene therapy, plasminogen, restenosis
Abbreviations:
aFGF, acidic fibroblast growth factors (also FGF1); ANG, angiopoietins; ARNT, arylhydrocarbon-receptor nuclear translocator; bFGF, basic fibroblast growth factor (also FGF2); FGF, fibroblast growth factors; FLK1, VEGF receptor-2; FLT1, VEGF receptor-1; HIF, hypoxia-inducible factor; IGF, insulin-like growth factor; MMPs, matrix metalloproteinases; PAs, plasminogen activators; PAI-1, plasminogen activator inhibitor-1; PDGF, platelet-derived growth factor; PlGF, placental growth factor; TF, tissue factor; TFPI, tissue factor pathway inhibitor; TGF-
, transforming growth factor-; TIE1, tyrosine kinase with immunoglobulin and epidermal growth factor homology domains; TIE2/TEK, tunica interna endothelial cell kinase; TIMPs, tissue inhibitor of matrix metalloproteinases; TNF-
, tubular necrosis factor-; t-PA, tissue-type PA; u-PA, urokinase-type plasminogen activator; u-PAR, urokinase plasminogen activator receptor; VE, vascular endothelial; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor
